Klug entscheiden in der Infektiologie

Literaturnachweise

  1. Kaasch AJ, et al.: Staphylococcus aureus bloodstream infection: a pooled analysis of five prospective, observational studies. J Infect 2014; 68: 242–51.
  2. Lopes-Cortes L,et al.: Impact of an evidence- based bundle intervention in the quality-of-care management and outcome of Staphylococcus aureus bacteremia. Clin Infect Dis 2013; 57: 1125–33.
  3. Fries BL, et al.: Infectious diseases consultation and the management of Staphylococcus aureus bacteremia. Clin Infect Dis 2014; 58: 598–9.
  4. Thwaites GE, et al.: Clinical management of Staphylococcus aureus bacteraemia. Lancet Infect Dis 2011; 11: 208–22.
  5. Holland TL, et al.: Clinical management of Staphylococcus aureus bacteremia: a review. JAMA 2014; 312: 1330–41.
  6. Levy MM, et al.: Outcomes of the surviving sepsis campaign in intensive care units in the USA and Europe: a prospective cohort study. Lancet Infect Dis 2012; 12: 919–24.
  7. Kumar A, et al.: Duration of hypotension before initiation of effective antimicrobial therapy is the critical determinant of survival in human septic shock. Crit Care Med 2006; 34: 1589–96.
  8. Dellinger RP, et al.: Surviving Sepsis Campaign: International Guidelines for Management of Severe Sepsis and Septic Shock. Crit Care Med 2013; 41: 580–637.
  9. S-2k Leitlinie AWMF-Register-Nr. 079/001: Sepsis – Diagnose, Prävention, Therapie und Nachsorge (2010).
  10. Bödeker B, et al.: Why are older adults and individuals with underlying chronic diseases in Germany not vaccinated against flu? A population-based study. BMC Public Health 2015; 15: 1–10.
  11. Uyeki TM: Preventing and controlling influenza with available interventions. NEJM 2014; 370: 789–91.
  12. Empfehlungen der Ständigen Impfkommission (STIKO) am Robert-Koch-Institut/ Stand: August 2015: Epidemiol Bulletin 2015; 34: 327–62.
  13. influenza.rki.de/Wochenberichte/ 2015_2016/2015–41.pdf (letzter Zugriff: 18. 10. 2015).
  14. www.flunewseurope.org/ (letzter Zugriff: 18. 10. 2015).
  15. www.impfen-info.de (letzter Zugriff: 18. 10. 2015).
  16. Mina MJ, et al.: Long-term measles-induced immunomodulation increases overall childhood infectious disease mortality. Science 2015; 348: 694–9.
  17. Demicheli V, et al.: Vaccines for measles, mumps and rubella in children. Cochrane Database Syst Rev, 2012; 15, DOI: 10.1002/14651858.CD004407.pub3.
  18. Überblick über die Epidemiologie der Masern in 2014 und aktuelle Situation in 2015 in Deutschland: Epidemiol Bulletin 2015; 10: 69–79.
  19. www.measlesrubellainitiative.org/ (letzter Zugriff 15. 10. 2015).
  20. www.who.int/mediacentre/factsheets/ fs286/en/ (letzter Zugriff 15. 10. 2015).
  21. MacGregor RR, Graziani AL: Oral administration of antibiotics: a rational alternative to the parenteral route. Clin Infect Dis 1997; 24: 457–67.
  22. Nathwani D, et al.: Implementing criteriabased early switch/early discharge programmes: a European perspective. Clin Microbiol Infect 2015; 21: S47–55.
  23. S3 Leitlinie AWMF-Register-Nr. 092/001: Strategie zur Sicherung rationaler Antibiotika- Anwendung im Krankenhaus (2013).
  24. S3 Leitlinie AWMF-Register-Nr. 082/001: Epidemiologie, Diagnostik, antimikrobielle Therapie und Management von erwachsenen Patienten mit ambulant erworbenen tiefen Atemwegsinfektionen (akute Bronchitis, akute Exazerbation einer chronischen Bronchitis, Influenza und andere respiratorische Virusinfektionen) sowie ambulant erworbener Pneumonie (2009).
  25. Shapiro DJ, et al.: Antibiotic prescribing for adults in ambulatory care in the USA, 2007–09. J Antimicrob Chemother 2014; 69: 234–40.
  26. Barnett ML, Linder JA: Antibiotic prescribing for adults with acute bronchitis in the United States, 1996–2010. JAMA 2014; 311: 2020–2.
  27. Little P, et al.: Amoxicillin for acute lowerrespiratory- tract infection in primary care when pneumonia is not suspected: a 12-country, randomised, placebo-controlled trial. Lancet Inf Dis 2013; 13: 123–9.
  28. Hersh AL, et al.: American Academy of Pediatrics Committee on Infectious Diseases. Principles of judicious antibiotic prescribing for upper respiratory tract infections in pediatrics. Pediatrics 2013; 132: 1146–54
  29. S3 Leitlinie DEGAM-Nr. 11. Husten (2014).
  30. Zalmanovici TA, Lador A, Sauerbrun-Cutler MT, et al.: Antibiotics for asymptomatic bacteriuria. Cochrane Database Syst Rev 2015, DOI: 10.1002/ 14651858.CD009534.pub2.
  31. Weiskopf J, Scott S: Asymptomatic bacteriuria, what are you treating? JAMA internal medicine 2015; 175: 344–5.
  32. Nicolle LE: Management of asymptomatic bacteriuria in pregnant women. Lancet Infect Dis 2015, DOI: 10.1016/S1473–3099(15)00145–0.
  33. Coussement J, Abramowicz D: Should we treat asymptomatic bacteriuria after renal transplantation? Nephrology, dialysis, transplantation 2014; 29: 260–2.
  34. S3 Leitlinie DEGAM-Nr. 1. Brennen beim Wasserlassen (2009).
  35. S3 Leitlinie AWMF-Register-Nr. 043/044. Epidemiologie, Diagnostik, Therapie und Management unkomplizierter bakterieller ambulant erworbener Harnwegsinfektionen bei erwachsenen Patienten (2010).
  36. Meersseman W, Lagrou K, Spriet I, et al.: Significance of the isolation of candida species from airway samples in critically ill patients: a prospective, autopsy study. Intensive Care Med 2009; 35: 1526–31.
  37. Lindau S, et al.: Antifungal therapy in patients with pulmonary Candida spp. Colonization may have no beneficial effects. Journal of Intensive Care 2015; 31: 1–9.
  38. Cornely OA, Bassetti M, Calandra T, et al.: ESCMID* guideline for the diagnosis and management of Candida diseases 012: non-neutropenic adult patients. Clin Microbiol Infect 2012; 18: 19–37.
  39. PEG-Empfehlungen: „Perioperative Antibiotikaprophylaxe“, 2010.
  40. S1 Leitlinie AWMF-Register Nr. 029/ 022. Perioperative Antibiotikaprophylaxe (2012).
  41. Bratzler DW, et al.: Clinical practice guidelines for antimicrobial prophylaxis in surgery, Am J Health-Syst Pharm 2013; 70: 195–283.
  42. ten Oever J, et al.: Utility of immune response- derived biomarkers in the differential diagnosis of inflammatory disorders. J Infect 2015; Sep 30. DOI: 10.1016/j.jinf.2015.09.007.
  43. Galarraga B, et al.: C-reactive protein: the underlying cause of microvascular dysfunction in rheumatoid arthritis. Rheumatology 2008; 47: 1780–4.
  44. Auer J, et al.: C-reactive protein in patients with acute myocardial infarction. Circulation. 2004; 109: E20.
  45. Gabay C, Kushner I: Acute-phase proteins and other systemic responses to inflammation. N Engl J Med 1999; 340: 448–54.

Um die unsere Webseite optimal gestalten zu können, werden Cookies verwendet. Durch die weitere Nutzung der Webseite der DGIM stimmen Sie der Verwendung von Cookies zu. Weitere Informationen zu Cookies und zum Datenschutz erfahren Sie hier

Checkbox kommt...